Classical drug development is undoubtedly indication- and product-driven. Simply put, a preclinically developed substance is optimised for clinical application in an appropriate galenic preparation and, in the best case, brought to market maturity in various phases of clinical development. Sven Engel at SynapCon GmbH talks more about personalised medicine.
